Aperture Investors’s Novo Nordisk NVO Stock Holding History

Aperture Investors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.38M	Hold	70,439	–	–	0.31%	63
2026 Q1	$2.59M	Sell	70,439 -28,682	-29%	-$1.36M	0.33%	63
2025 Q4	$5.04M	Hold	99,121	–	–	0.58%	44
2025 Q3	$5.5M	Buy	99,121 +35,317	+55%	+$2.07M	0.75%	37
2025 Q2	$4.4M	Hold	63,804	–	–	0.57%	51
2025 Q1	$4.43M	Buy	63,804 +9,344	+17%	+$772K	0.57%	51
2024 Q4	$4.68M	Hold	54,460	–	–	0.59%	47
2024 Q3	$6.48M	Hold	54,460	–	–	0.82%	35
2024 Q2	$7.77M	Hold	54,460	–	–	1.14%	31
2024 Q1	$6.99M	Buy	54,460 +22,842	+72%	+$2.72M	0.9%	40
2023 Q4	$3.27M	Sell	31,618 -30,534	-49%	-$3.02M	0.58%	46
2023 Q3	$5.65M	Sell	62,152 -4,788	-7%	-$422K	0.9%	35
2023 Q2	$5.42M	Hold	66,940	–	–	0.64%	43
2023 Q1	$5.33M	Buy	66,940 +10,208	+18%	+$724K	0.74%	38
2022 Q4	$3.84M	Sell	56,732 -22,050	-28%	-$1.29M	0.63%	40
2022 Q3	$3.92M	Buy	78,782 +53,410	+211%	+$2.86M	0.64%	41
2022 Q2	$1.41M	Buy	+25,372	New	+$1.41M	0.24%	55

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Aperture Investors's NVO Position: Q2 2026 in Review

Aperture Investors held its Novo Nordisk (NVO) position steady in Q2 2026 at 70,439 shares worth $3.38M. The position accounts for 0.31% of the portfolio, ranked #63.

Aperture Investors first reported a position in NVO in Q2 2022 and has held it in 17 quarters since. The position peaked at $7.77M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Aperture Investors held 70,439 shares of Novo Nordisk worth $3.38M as of Q2 2026.
Aperture Investors left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.31% of Aperture Investors's portfolio in Q2 2026, its #63 holding.
Aperture Investors first reported a position in Novo Nordisk in Q2 2022 and has held it in 17 quarters since.
Aperture Investors's Novo Nordisk position peaked at $7.77M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Aperture Investors's 13F filing for Q2 2026, filed 14 Aug 2026.